Valneva adds $95M in equity deal with partner Pfizer
Amends 2020 deal for Phase III Lyme disease candidate VLA15
Valneva is adding some cushion to its cash position through an equity purchase agreement with partner Pfizer.
The French vaccines company Valneva SE (Euronext:VLA; NASDAQ:VALN) said it agreed to sell an 8.1% stake to partner Pfizer Inc. (NYSE:PFE) for €90.5 million ($95.2 million) as part of an amendment to their 2020 deal to co-develop and commercialize VLA15, a Valneva Lyme disease vaccine. ...